The Prometheus v. Mayo case, what Hal Wegner calls “Metabolite déjà vu II,” has represented perhaps the most troubling development for medical treatment patents in recent times. The case concerns a patent for a means to measure the level of 6-thioguinine (6-TG) and 6-methylmercaptopurine (6-MMP), which indicates that an adjustment in drug dosage may be […]